Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer

BJU International

Volumn 83, Issue 7, 1999, Pages 801-806

  Sarosdy, M F ^a,i   Schellhammer, P F ^b   Soloway, M S ^c   Vogelzang, N J ^d   Crawford, E D ^e   Presti, J ^f   Chodak, G W ^g   Mitchell, P ^h   Porter, L ^h  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g WEISS MEMORIAL HOSPITAL   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Goserelin acetate; Luteinizing hormone releasing hormone analogues; Prostatic neoplasms; Zoladex

Indexed keywords

GONADORELIN AGONIST; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION; TESTOSTERONE BLOOD LEVEL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; GOSERELIN; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TESTOSTERONE; TREATMENT OUTCOME;

EID: 0032955357     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1999.00028.x     Document Type: Article

References (10)

1. Kerle D, Williams G, Ware H, Bloom SR. Failure of long term luteinizing hormone releasing hormone treatment for prostatic cancer to suppress serum luteinizing hormone and testosterone. Br Med J 1994; 289: 468-9
2. Williams G, Kerle D, Griffin S, Dunlop H, Bloom SR. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system. Br Med J 1994; 289: 1580-1
3. Turkes A, Turkes A, Peeling B, Griffiths K. The use of a depot LHRH analogue, Zoladex, in the treatment of prostatic cancer: a dose-interval study. Med Sci Res 1987; 15: 477
4. Grant JBF, Ahmed SR, Shalet SM, Costello B, Howell A, Blacklock NJ. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy. Br J Urol 1986; 58: 539-44
5. Debruyne FM, Dijkman GA, Lee DCH, Witjes PJ. A new- long acting formulation of the luteinizing hormone- releasing hormone analogue, goserelin: results of studies in prostate cancer, J Urol 1996; 155: 1352-4
6. Fernandez del Moral P, Dijkman GA, Debruyne FMJ, Witjes WPJ, Kolvenbag GJCM. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Urology 1996; 48: 894-900
7. Dijkman GA, Fernandez del Moral P, Plasman JWMH et al. A new long-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot. Eur Urol 1990; 18: 22-5
8. Slack NH, Murphy GP. Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am 1984; 11: 337-42
9. Cleary PD, Morrissey G, Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res 1995; 4: 207-20
10. Vogelzang NJ, Chodak GW, Soloway MS et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995; 46: 220-6